| Literature DB >> 29971022 |
Maira Giannelou1,2, Dimitrios Tseronis2,3, Eleni Antypa4, Clio P Mavragani1,3,5.
Abstract
Objectives: Patients with systemic lupus erythematosus (SLE) are characterized by increased cardiovascular disease (CVD) risk as well as heightened rates of psychological distress. Since a link between psychological issues and CV morbidity has been previously suggested, the influence of psychological burden on subclinical atherosclerosis in SLE patients was investigated.Entities:
Keywords: anxiety; depression; fatigue; lupus; personality; sleep; subclinical atherosclerosis
Year: 2018 PMID: 29971022 PMCID: PMC6018100 DOI: 10.3389/fpsyt.2018.00246
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Traditional and disease related predictors of carotid/femoral plaque and arterial wall thickening (defined as IMT scores>0.90 mm) in 71 patients with SLE included in the study.
| Age (mean ± SD) years | 52.8 ± 11.6 | 35.5 ± 8.2 | <0.001 | 56.46 ± 11.0 | 38.76 ± 9.9 | <0.001 |
| Female sex (%) | 95 | 93.5 | ns | 92.3 | 93.3 | ns |
| Disease duration (mean ± SD) years | 13.9 ± 9.2 | 6.7 ± 6.3 | 0.001 | 12.9 ± 9.5 | 9.4 ± 8.1 | ns |
| BMI (mean ± SD) kg/m2 | 25.4 ± 4.2 | 24.0 ± 5.2 | ns | 26.6 ± 3.8 | 23.8 ± 4.9 | 0.004 |
| FH of CVD (%) | 20 | 12.9 | ns | 23.1 | 13.3% | ns |
| Diabetes mellitus (%) | 5 | 6.5 | ns | 7.7 | 4.4 | ns |
| Hypertension (%) | 47.5 | 6.5 | <0.001 | 61.5 | 11.1 | <0.001 |
| Smoking (pack/years) | 14.2 ± 20.3 | 7.4 ± 11.9 | ns | 17.4 ± 23.3 | 7.7 ± 11.7 | ns |
| Cholesterol levels (mean ± SD) mg/dl | 191 ± 34 | 171 ± 34 | 0.027 | 194 ± 38 | 174 ± 31 | 0.028 |
| Triglyceride (mean ± SD) mg/dl | 131 ± 50 | 111 ± 62 | 0.047 | 141 ± 53 | 111 ± 55 | 0.014 |
| LDL (mean ± SD) mg/dl | 113 ± 41 | 100 ± 28 | ns | 120 ± 41 | 100 ± 31 | 0.028 |
| HDL (mean ± SD) mg/dl | 49 ± 17 | 48 ± 18 | ns | 46.9 ± 14.1 | 49.6 ± 19.7 | ns |
| Uric acid (mean ± SD) mg/dl | 4.9 ± 1.7 | 4.2 ± 1.3 | ns | 5.3 ± 1.6 | 4.2 ± 1.4 | 0.004 |
| ANA ≥ 1:320 (%) | 97.5 | 90.3 | ns | 96 | 93.3 | ns |
| Positive anti-dsDNA titers (%) | 58.3 | 50 | ns | 52 | 62 | ns |
| Current steroid dose (mean ± SD) mg | 9.3 ± 11.4 | 15.3 ± 17 | ns | 6.9 ± 8.0 | 14.8 ± 16.3 | 0.042 |
| Total steroid dose (mean ± SD) gr | 33.3 ± 31.8 | 17.1 ± 17.2 | ns | 26.9 ± 30.2 | 25.7 ± 26.1 | ns |
| Abnormal renal function (%) | 10 | 6.5 | ns | 15.4 | 4.4 | ns |
| SLEDAI (mean ± SD) | 9.1 ± 6.8 | 8.9 ± 8.8 | ns | 9.7 ± 7.5 | 8.7 ± 7.9 | ns |
IMT, intima-media thickness; BMI, body mass index; CVD, cardiovascular disease; FH, family history; LDL, low density lipoproteins;HDL, high density lipoproteins; ANA, anti-nuclear antibodies; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
Figure 1Psychometric scores (expressed in mean ± SD) in 71 SLE patients with and without plaque formation (A) and arterial wall thickening (B), defined as IMT scores>0.90 mm).Only statistical significant differences are displayed, *p < 0.05, **p < 0.01. IMT, intima-media thickness; STAI, State-Trait Anxiety Inventory; EPQ, Eysenck Personality Questionnaire Scale; Zung, Zung Depression Scale; Insomnia, Athens Insomnia Scale; FACIT-F, Functional Assessment of Chronic Illness Therapy–Fatigue scale.